Zevra Therapeutics, Inc.

NASDAQ:ZVRA

Biotechnology

Healthcare
$9.28 +2.44%

+$0.31 today

Market cap
$552.20M
Beta
0.89
P/E (TTM)
6.1
EPS (TTM)
$2.13
52W Low $7.16High $14.27

Volume 0.62M

Average 1.43M

ZVRA Common Stock

The par or stated value of issued common shares, plus paid-in capital where reported together.

Zevra Therapeutics, Inc.NASDAQ: ZVRA

Common Stock · Q1 FY2026 · quarter ended Mar 2026

Common stock rises 20.0% from a year ago

Common stock stood at $6K at the end of Q1 FY2026, up 20.0% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at +26.0% a year.

Context

  • Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Common stock increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether common stock keeps rising in the next quarterly balance sheet after a +20.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$6K+0.0% QoQ
Last fiscal yearDec 2025
$6K+20.0% YoY
Year agoMar 2025
$5K+20.0% since
Common Stock past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+20.0%——
1 year+20.0%——
3-year CAGR+26.0%——
5-year CAGR——
10-year CAGR——

Common Stock history

USD · from the balance sheet

Latest · FY2025
6K USD
Year-over-year change
+20.0%
4-year CAGR
+10.7%

Common Stock vs competitors

How ZVRA compares with its peers on the latest reported figures

  • ZVRA's Mar 2026 common stock of $6K is the 8th highest of the 11 companies compared; the peer median is $38K.
  • Its year-over-year change of +20.0% is the 2nd highest of 10, against a peer median of +2.6%.
  • Common stock amounts to 0.0% of total assets for ZVRA, versus a peer median of 0.0%.
ZVRA Competitors Peer median
Common Stock for ZVRA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
XENEXenon Pharmaceuticals Inc.Sep 2026$2.49B +69.0%+14.5%207.8%
ALKSAlkermes plcSep 2026$1.85M +2.6%+2.3%0.0%
GHRSGH Research PLCMar 2026$1.55M +0.0%+6.0%0.6%
NBIXNeurocrine Biosciences, Inc.Sep 2026$100K +0.0%+0.0%0.0%
SUPNSupernus Pharmaceuticals, Inc.Jun 2026$58K +3.6%+1.8%0.0%
NMRANeumora Therapeutics, Inc. Common StockMar 2026$18K +12.5%+78.3%0.0%
PRAXPraxis Precision Medicines, Inc.Sep 2026$15K +7.1%+44.2%0.0%
ZVRAZevra Therapeutics, Inc.Mar 2026$6K +20.0%+26.0%0.0%
MPLTMapLight Therapeutics, Inc.Mar 2026$5K ——0.0%
ANROAlto Neuroscience, Inc.Mar 2026$3K +0.0%+44.2%0.0%
JAZZJazz Pharmaceuticals plcSep 2026$0 -100.0%-53.8%0.0%
Peer median (excluding ZVRA) $38K+2.6%+6.0%0.0%

Competitors are the stored peer set for ZVRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents112.35M65.47M43.05M33.79M62.41M
Short-term Investments017.38M24.69M35.71M128.6M
Net Receivables1.53M8.3M17.38M10.51M23.26M
Inventory0024.08M1.97M1.74M
Other Current Assets252K1.11M(23.43M)3.02M7M
Total Current Assets115.06M92.83M86.94M86.03M223.01M
Property, Plant & Equipment (Net)2.03M1.78M1.53M1.01M1.7M
Goodwill004.7M4.7M4.7M
Intangible Assets0069.23M68.99M6.42M
Long-term Investments15.42M20M06.01M47.88M
Tax Assets00000
Other Non-current Assets438K724K9.94M11.38M1.02M
Total Non-current Assets17.89M22.51M85.39M92.1M61.72M
Total Assets132.94M115.34M172.33M178.13M284.73M
Account Payables516K3.61M13.99M13.08M2.48M
Short-term Debt04.66M37.7M00
Tax Payables00014.43M13.71M
Deferred Revenue00000
Other Current Liabilities821K719K10.82M3.2M22.67M
Total Current Liabilities4.23M12.02M73.72M34.07M39.28M
Long-term Debt012.8M5.07M59.5M61.93M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities355K14.55M31.22M44.52M28.01M
Total Non-current Liabilities1.59M28.2M36.74M104.4M90.8M
Total Liabilities5.82M40.22M110.46M138.46M130.07M
Common Stock4K3K4K5K6K
Retained Earnings(267.03M)(353.73M)(399.78M)(505.29M)(422.06M)
Accumulated OCI(0)113K(43K)631K(764K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity127.12M75.12M61.86M39.67M154.66M
Total Debt1.61M18.78M43.77M60.3M63.21M
Net Debt(110.74M)(46.69M)716K26.51M800K

Zevra Therapeutics, Inc.

NASDAQ:ZVRA

Intrinsic Alpha fair value

Locked

Current Price

$9.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.